# Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors

> **NCT00920595** · PHASE1 · COMPLETED · sponsor: **Cephalon** · enrollment: 26 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** CEP-9722

## Key facts

- **NCT ID:** NCT00920595
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2012-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920595, "Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00920595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*